New developments in the management of Waldenström macroglobulinemia

References

• WaldenströmJIncipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia — a new syndrome?J Intern Med19441173–4216247
   Google Scholar
• CastilloJJOlszewskiAJKananSMeidKHunterZRTreonSPOverall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results databaseBr J Haematol20151691818925521528
   PubMed Web of Science ®Google Scholar
• KristinssonSYElorantaSDickmanPWPatterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005Am J Hematol2013881606523165980
   PubMed Web of Science ®Google Scholar
• SekharJSanfilippoKZhangQTrinkausKVijRMorgenszternDWaldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005Leuk Lymphoma20125381625162622239669
   PubMed Web of Science ®Google Scholar
• OlszewskiAJTreonSPCastilloJJEvolution of management and outcomes in Waldenstrom macroglobulinemia: a population-based analysisOncologist Epub2016729
   Web of Science ®Google Scholar
• KristinssonSYBjorkholmMGoldinLRMcMasterMLTuressonILandgrenORisk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in SwedenBlood200811283052305618703425
   PubMed Web of Science ®Google Scholar
• KapoorPDiagnosis and management of Waldenstrom macroglobulinemia mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesJAMA Oncol Epub201715
   Web of Science ®Google Scholar
• AnsellSMKyleRAReederCBDiagnosis and management of Waldenstrom macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesMayo Clin Proc201085982483320702770
   PubMed Web of Science ®Google Scholar
• LandgrenOTagejaNMYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenstrom’s macroglobulinemiaLeukemia20142891799180324573383
   PubMed Web of Science ®Google Scholar
• TreonSPXuLYangGMYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemiaN Engl J Med2012367982683322931316
   PubMed Web of Science ®Google Scholar
• YangGZhouYLiuXA mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemiaBlood201312271222123223836557
   PubMed Web of Science ®Google Scholar
• TreonSPCaoYXuLYangGLiuXHunterZRSomatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemiaBlood2014123182791279624553177
   PubMed Web of Science ®Google Scholar
• MoriuchiMMoriuchiHTurnerWFauciASCloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entryJ Immunol19971599432243299379028
   PubMed Web of Science ®Google Scholar
• CaruzASamsomMAlonsoJMGenomic organization and promoter characterization of human CXCR4 geneFEBS Lett199842622712789599023
   PubMed Web of Science ®Google Scholar
• HunterZRXuLYangGThe genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisBlood2014123111637164624366360
   PubMed Web of Science ®Google Scholar
• XuLHunterZRTsakmaklisNClonal architecture of CXCR4 WHIM-like mutations in Waldenstrom macroglobulinaemiaBr J Haematol2016172573574426659815
   PubMed Web of Science ®Google Scholar
• HunterZRXuLYangGTranscriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstrom macroglobulinemiaBlood2016128682783827301862
   PubMed Web of Science ®Google Scholar
• Garcia-SanzRMontotoSTorrequebradaAWaldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 casesBr J Haematol2001115357558211736938
   PubMed Web of Science ®Google Scholar
• GhobrialIMAre you sure this is Waldenstrom macroglobulinemia?Hematology Am Soc Hematol Educ Program2012201258659423233639
   PubMed Web of Science ®Google Scholar
• KapoorPPaludoJVallumsetlaNGreippPRWaldenstrom macroglobulinemia: what a hematologist needs to knowBlood Rev201529530131925882617
   PubMed Web of Science ®Google Scholar
• KyleRATreonSPAlexanianRPrognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemiaSemin Oncol200330211612012720119
   PubMed Web of Science ®Google Scholar
• GertzMAReederCBKyleRAAnsellSMStem cell transplant for Waldenstrom macroglobulinemia: an underutilized techniqueBone Marrow Transplant20124791147115321874060
   PubMed Web of Science ®Google Scholar
• LouwVJWebbMJPrognosis and treatment of Waldenstrom’s macroglobulinemiaTransfus Apher Sci201042219319720117052
   PubMed Web of Science ®Google Scholar
• JohnsonSABirchallJLuckieCOscierDGOwenRGGuidelines on the management of Waldenstrom macroglobulinaemiaBr J Haematol2006132668369716487169
   PubMed Web of Science ®Google Scholar
• LeblondVKastritisEAdvaniRTreatment recommendations for Waldenstrom macroglobulinemia from the Eighth International Workshop on WMBlood2016128101321132827432877
   PubMed Web of Science ®Google Scholar
• SzczepiorkowskiZMWintersJLBandarenkoNGuidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Apheresis Applications Committee of the American Society for apheresisJ Clin Apher20102538317720568098
   PubMed Web of Science ®Google Scholar
• TreonSPAgusDBLinkBCD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemiaJ Immunother (1991)200124327227911395644
   PubMed Web of Science ®Google Scholar
• TreonSPAgusTBLinkBCD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemiaJ Immunother2001243272279
   Web of Science ®Google Scholar
• GertzMARueMBloodEKaminerLSVesoleDHGreippPRMulticenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)Leuk Lymphoma200445102047205515370249
   PubMed Web of Science ®Google Scholar
• TreonSPBranaganARHunterZSantosDTournhilacOAndersonKCParadoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemiaAnn Oncol200415101481148315367407
   PubMed Web of Science ®Google Scholar
• TreonSPEmmanouilidesCKimbyEExtended rituximab therapy in Waldenstrom’s macroglobulinemiaAnn Oncol200516113213815598950
   PubMed Web of Science ®Google Scholar
• GhobrialIMFonsecaRGreippPRInitial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group StudyCancer2004101112593259815493038
   PubMed Web of Science ®Google Scholar
• LiSCChenYCEvensAMRituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphismAm J Hematol2010851081081220730791
   PubMed Web of Science ®Google Scholar
• WolachOBaireyOLahavMLate-onset neutropenia after rituximab treatment: case series and comprehensive review of the literatureMedicine (Baltimore)201089530831820827108
   PubMed Web of Science ®Google Scholar
• WolachOShpilbergOLahavMNeutropenia after rituximab treatment: new insights on a late complicationCurr Opin Hematol2012191323822080846
   PubMed Web of Science ®Google Scholar
• WengWKNegrinRSLavoriPHorningSJImmunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab- induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphomaJ Clin Oncol201028227928419933905
   PubMed Web of Science ®Google Scholar
• CastilloJJKananSMeidKManningRHunterZRTreonSPRituximab intolerance in patients with Waldenstrom macroglobulinaemiaBr J Haematol2016174464564826523929
   PubMed Web of Science ®Google Scholar
• FurmanRREradatHSwitzkyJCA phase II trial of ofatumumab in subjects with Waldenstrom’s macroglobulinemiaBlood2010116211795179520530284
   PubMed Web of Science ®Google Scholar
• TreonSPHow I treat Waldenstrom macroglobulinemiaBlood2015126672173226002963
   PubMed Web of Science ®Google Scholar
• DimopoulosMAAnagnostopoulosAKyrtsonisMCPrimary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamideJ Clin Oncol200725223344334917577016
   PubMed Web of Science ®Google Scholar
• KastritisEGavriatopoulouMKyrtsonisMCDexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 studyBlood2015126111392139426359434
   PubMed Web of Science ®Google Scholar
• RummelMJNiederleNMaschmeyerGBendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialLancet201338198731203121023433739
   PubMed Web of Science ®Google Scholar
• TedeschiAPicardiPFerreroSBendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemiaLeuk Lymphoma20155692637264225651423
   PubMed Web of Science ®Google Scholar
• TreonSPHanzisCTripsasCBendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemiaClin Lymphoma Myeloma Leuk201111113313521454214
   PubMed Web of Science ®Google Scholar
• CastilloJJGustineJMeidKDubeauTGhobrialIMTreonSPLower doses of bendamustine are not associated with lower response rates in previously untreated patients with Waldenström macroglobulinemiaBlood20161282229692969
   Web of Science ®Google Scholar
• LeblondVJohnsonSChevretSResults of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphomaJ Clin Oncol201331330130723233721
   PubMed Web of Science ®Google Scholar
• DimopoulosMAKastritisEOwenRGTreatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood201412491404141125027391
   PubMed Web of Science ®Google Scholar
• TreonSPProteasome inhibitors in Waldenstrom macroglobulinemiaBlood2013122193243324424203925
   PubMed Web of Science ®Google Scholar
• KapoorPAnother bidder (BDR) revisitsBlood2017129439840028126954
   PubMed Web of Science ®Google Scholar
• TreonSPIoakimidisLSoumeraiJDPrimary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180J Clin Oncol200927233830383519506160
   PubMed Web of Science ®Google Scholar
• GhobrialIMXieWPadmanabhanSPhase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemiaAm J Hematol201085967067420652865
   PubMed Web of Science ®Google Scholar
• TreonSPTripsasCKMeidKCarfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemiaBlood2014124450351024859363
   PubMed Web of Science ®Google Scholar
• ChauhanDTianZZhouBIn vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cellsClin Cancer Res201117165311532121724551
   PubMed Web of Science ®Google Scholar
• RichardsonPGBazRWangMPhase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsBlood201412471038104624920586
   PubMed Web of Science ®Google Scholar
• HurchlaMAGarcia-GomezAHornickMCThe epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effectsLeukemia201327243044022763387
   PubMed Web of Science ®Google Scholar
• DimopoulosMAZomasAViniouNATreatment of Waldenstrom’s macroglobulinemia with thalidomideJ Clin Oncol200119163596360111504741
   PubMed Web of Science ®Google Scholar
• ColemanMLeonardJLyonsLSzelenyiHNiesvizkyRTreatment of Waldenstrom’s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasoneSemin Oncol200330227027412720151
   PubMed Web of Science ®Google Scholar
• TreonSPSoumeraiJDBranaganARThalidomide and rituximab in Waldenstrom macroglobulinemiaBlood2008112124452445718713945
   PubMed Web of Science ®Google Scholar
• DimopoulosMATsatalasCZomasATreatment of Waldenstrom’s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasoneSemin Oncol200330226526912720150
   PubMed Web of Science ®Google Scholar
• TreonSPSoumeraiJDBranaganARLenalidomide and rituximab in Waldenstrom’s macroglobulinemiaClin Cancer Res200915135536019118065
   PubMed Web of Science ®Google Scholar
• GhobrialIMWitzigTEGertzMLong-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemiaAm J Hematol201489323724224716234
   PubMed Web of Science ®Google Scholar
• TreonSPTripsasCKIoakimidisLProspective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom’s macroglobulinemiaBlood2011118212951295121734234
   PubMed Web of Science ®Google Scholar
• GhobrialIMReddRArmandPPhase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemiaLeukemia201529122338234626139427
   PubMed Web of Science ®Google Scholar
• de RooijMFMKuilAKraanWIbrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemiaHaematologica20161013e111e11526635033
   PubMed Web of Science ®Google Scholar
• CastilloJJGustineJNMeidKIdelalisib in Waldenstrom macroglobulinemia: high incidence of hepatotoxicityLeuk Lymphoma20175841002100427562445
   PubMed Web of Science ®Google Scholar
• TreonSPTournilhacOBranaganARClinical responses to sildenafil in Waldenstrom’s macroglobulinemiaClin Lymphoma20045320520715636699
   PubMedGoogle Scholar
• PalsSTKerstenMJSpaargarenMTargeting cell adhesion and homing as strategy to cure Waldenström’s macroglobulinemiaBest Pract Res Clin Haematol201629216116827825462
   PubMed Web of Science ®Google Scholar
• TreonSPTripsasCKMeidKIbrutinib in previously treated Waldenstrom’s macroglobulinemiaN Engl J Med2015372151430144025853747
   PubMed Web of Science ®Google Scholar
• DimopoulosMATrotmanJTedeschiAIbrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialLancet Oncol Epub2016129
   Google Scholar
• CaoYHunterZLiuXThe WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s macroglobulinemiaLeukemia201529116917624912431
   PubMed Web of Science ®Google Scholar
• CaoYHunterZRLiuXCXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cellsBr J Haematol2015168570170725371371
   PubMed Web of Science ®Google Scholar
• TreonSPXuLHunterZMYD88 mutations and response to ibrutinib in Waldenstrom’s macroglobulinemiaN Engl J Med20153736584586
   PubMed Web of Science ®Google Scholar
• ByrdJCBrownJRO’BrienSIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaN Engl J Med2014371321322324881631
   PubMed Web of Science ®Google Scholar
• LeongDPCaronFHillisCThe risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysisBlood2016128113814027247135
   PubMed Web of Science ®Google Scholar
• GustineJNMeidKDubeauTETreonSPCastilloJJAtrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemiaAm J Hematol2016916E312E31326994323
   PubMed Web of Science ®Google Scholar
• McMullenJRBoeyEJOoiJYSeymourJFKeatingMJTamCSIbrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signalingBlood2014124253829383025498454
   PubMed Web of Science ®Google Scholar
• LevadeMDavidEGarciaCIbrutinib treatment affects collagen and von Willebrand factor-dependent platelet functionsBlood2014124263991399525305202
   PubMed Web of Science ®Google Scholar
• HivertBCaronCPetitSClinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemiaBlood2012120163214322122896002
   PubMed Web of Science ®Google Scholar
• YangGLiuXChenJTargeting IRAK1/IRAK4 signaling in Waldenstrom’s macroglobulinemiaBlood20151262340044004
   Web of Science ®Google Scholar
• YangGBuhrlageSJTanLHCK is a survival determinant trans-activated by mutated MYD88, and a direct target of ibrutinibBlood2016127253237325227143257
   PubMed Web of Science ®Google Scholar
• YangGBuhrlageSTanLHCK is a highly relevant target of ibrutinib in MYD88 mutated Waldenstrom’s macroglobulinemia and diffuse large B-cell lymphomaBlood201512623705705
   Web of Science ®Google Scholar
• CaoYYangGHunterZRThe BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cellsBr J Haematol2015170113413825582069
   PubMed Web of Science ®Google Scholar
• PaulusAChittaKSAkhtarSAurora kinase is a therapeutic target in ibrutinib-resistant Waldenstrom macroglobulinemia: in-silico target identification and in-vitro validationBlood20151262327542754
   Web of Science ®Google Scholar
• KyriakouCCanalsCSibonDHigh-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationJ Clin Oncol201028132227223220368570
   PubMed Web of Science ®Google Scholar
• KyriakouCBoumendilAFinelHAutologous stem cell transplantation (ASCT) for the treatment of patients with Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL). A risk factor analysis by the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working PartyBlood20141242167867825221805
   PubMed Web of Science ®Google Scholar
• KyriakouCCanalsCCornelissenJJAllogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationJ Clin Oncol201028334926493420956626
   PubMed Web of Science ®Google Scholar
• GertzMAKyleRAHyperviscosity syndromeJ Intensive Care Med199510312814110155178
   PubMedGoogle Scholar
• LetendreLKyleRAMonoclonal cryoglobulinemia with high thermal insolubilityMayo Clin Proc198257106296337121069
   PubMed Web of Science ®Google Scholar
• MichaelABLawesMKamalarajanMHuissoonAPrattGCryoglobulinaemia as an acute presentation of Waldenstrom’s macroglobulinaemiaBr J Haematol2004124556514871241
   PubMedGoogle Scholar
• Nobile-OrazioEMarmiroliPBaldiniLPeripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteinsNeurology1987379150615142442666
   PubMed Web of Science ®Google Scholar
• AdvaniRHBuggyJJSharmanJPBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesJ Clin Oncol2013311889423045577
   PubMed Web of Science ®Google Scholar
• FurmanRBilottiEGraefTSingle-agent ibrutinib demonstrates long-term activity and safety in patients with relapsed/refractory Waldenstrom’s macroglobulinemiaPaper presented at: HaematologicaVienna, Austria2015
   Google Scholar